Skip to search formSkip to main contentSkip to account menu

Oxyphenbutazone:MCnc:Pt:Ser/Plas:Qn

Known as: Oxyphenbutazone:Masse/Volume:Ponctuel:Sérum/Plasma:Numérique, ??????:????:????:??/??:??, Oxyphenbutazone:Concentration de masse:Temps ponctuel:Sérum/Plasma:Quantitatif 
National Institutes of Health

Related topics

Related topics

5 relations
OxyphenbutazonePlasPlasmaSerum

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1993
1993
[Incidence of drug side effects by symptoms and syndromes. From the experiences of the Comprehensive Hospital Drug Monitoring and the Swiss Drug Side Effect Center. As an example: allergic and pseudo…
From 1974 to 1989, 37,392 patients were admitted to the divisions of general internal medicine of the CHDM hospitals. 19,082 of… 
1988
1988
Physical characterization of two oxyphenbutazone pseudopolymorphs.
Two pseudopolymorphic forms of oxyphenbutazone, a benzene solvate (Solvate B) and a cyclohexane solvate (Solvate C), were… 
1973
1973
Experimental and Clinical Investigation of a Non-Hormonal Anti-Inflammatory Eye Ointment
The penetration of [14C]-labelled oxyphenbutazone (OPB = active substance of Tanderil® eye ointment) from a 10-percent eye… 
1972
1972
The Effect of Oxyphenbutazone (Tanderil) Eye Ointment on Viral Replication and Toxicity in the Rabbit Cornea
The anti-inflammatory agent oxyphenbutazone (Tanderil) when applied in ointment form in concentrations from 3 % to 50 % to the… 
1971
1971
[Treatment of typhoid and paratyphoid fever with the furazolidone-oxyphenbutazone combination].
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)